Clinical potential of allopurinol in the treatment of bipolar disorder

Indian Journal of Psychological Medicine

Volumn 36, Issue 2, 2014, Pages 218-220

  Bishnoi, Ram J ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84899714190     PISSN: 02537176     EISSN: 09751564     Source Type: Journal    
DOI: 10.4103/0253-7176.131008     Document Type: Letter

References (17)

1. Kraepelin E. Manic-Depressive Insanity and Paranoia. Edinburgh, Scotland: E & S Livingstone; 1921.
2. Machado-Vieira R, Lara DR, Souza DO, Kapczinski F. Purinergic dysfunction in mania: An integrative model. Med Hypotheses 2002;58:297-304.
3. Anumonye A, Reading HW, Knight F, Ashcroft GW. Uric-acid metabolism in manic-depressive illness and during lithium therapy. Lancet 1968;1:1290-3.
4. Machado-Vieira R, Lara DR, Souza DO, Kapczinski F. Therapeutic efficacy of allopurinol in mania associated with hyperuricemia. J Clin Psychopharmacol 2001;21:621-2.
5. Brooks SC, Linn JJ, Disney N. Serotonin, folic acid, and uric acid metabolism in the diagnosis of neuropsychiatric disorders. Biol Psychiatry 1978;13:671-84.
6. Barden N, Harvey M, Gagné B, Shink E, Tremblay M, Raymond C, et al. Analysis of single nucleotide polymorphisms in genes in the chromosome 12Q24.31 region points to P2RX7 as a susceptibility gene to bipolar affective disorder. Am J Med Genet B Neuropsychiatr Genet 2006;141:374-82.
7. Lucae S, Salyakina D, Barden N, Harvey M, Gagné B, Labbé M, et al. P2RX7, a gene coding for a purinergic ligand-gated ion channel, is associated with major depressive disorder. Hum Mol Genet 2006;15:2438-45.
8. Burnstock G. Historical review: ATP as a neurotransmitter. Trends Pharmacol Sci 2006;27:166-76.
9. Kilzieh N, Akiskal HS. Rapid-cycling bipolar disorder. An overview of research and clinical experience. Psychiatr Clin North Am 1999;22:585-607.
10. Lara DR, Dall'Igna OP, Ghisolfi ES, Brunstein MG. Involvement of adenosine in the neurobiology of schizophrenia and its therapeutic implications. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:617-29.
11. Pacher P, Nivorozhkin A, Szabó C. Therapeutic effects of xanthine oxidase inhibitors: Renaissance half a century after the discovery of allopurinol. Pharmacol Rev 2006;58:87-114.
12. Machado-Vieira R, Andreazza AC, Viale Cl, Zanatto V, Cereser V Jr, da Silva Vargas R, et al. Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: A possible role for lithium antioxidant effects. Neurosci Lett 2007;421:33-6.
13. Brunstein MG, Ghisolfi ES, Ramos FL, Lara DR. A clinical trial of adjuvant allopurinol therapy for moderately refractory schizophrenia. J Clin Psychiatry 2005;66:213-9.
14. Akhondzadeh S, Milajerdi MR, Amini H, Tehrani-Doost M. Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: A double-blind, randomized, placebo-controlled trial. Bipolar Disord 2006;8:485-9.
15. Machado-Vieira R, Soares JC, Lara DR, Luckenbaugh DA, Busnello JV, Marca G, et al. A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania. J Clin Psychiatry 2008;69:1237-45.
16. Fan A, Berg A, Bresee C, Glassman LH, Rapaport MH. Allopurinol augmentation in the outpatient treatment of bipolar mania: A pilot study. Bipolar Disord 2012;14:206-10.
17. Salvadore G, Viale CI, Luckenbaugh DA, Zanatto VC, Portela LV, Souza DO, et al. Increased uric acid levels in drug-naïve subjects with bipolar disorder during a first manic episode. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:819-21.